MP14-19 SALVAGE IMMUNE CHECKPOINT INHIBITOR (IO) PLUS TYROSINE KINASE INHIBITOR (TKI) COMBINATION THERAPY FOR METASTATIC RENAL CELL CARCINOMA (mRCC)
- Resource Type
- Source
- Journal of Urology. 206
- Subject
Standard of care Combination therapy business.industry medicine.drug_class Urology Immune checkpoint inhibitors urologic and male genital diseases medicine.disease Tyrosine-kinase inhibitor respiratory tract diseases Renal cell carcinoma Toxicity Cancer research Initial treatment Medicine business - Language
- ISSN
- 1527-3792
0022-5347